NCT05305664 - A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2022

Primary Completion Date

January 28, 2025

Study Completion Date

January 28, 2025

Conditions

Hyperlipoproteinemia(a)

Interventions

DRUG

Pelacarsen (TQJ230) 80 mg s.c.

Pelacarsen (TQJ230) 80 mg s.c. Q4W

DRUG

Corresponding Placebo

Placebo to Pelacarsen

Trial Locations (13)

Novartis Investigative Site, Berlin

Novartis Investigative Site, Göttingen

Novartis Investigative Site, Düsseldorf

Novartis Investigative Site, Cloppenburg

Novartis Investigative Site, Geilenkirchen

Novartis Investigative Site, Mainz

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, München

Novartis Investigative Site, Ulm

Novartis Investigative Site, Erlangen

Novartis Investigative Site, Würzburg

Novartis Investigative Site, Dresden

Novartis Investigative Site, Villingen-Schwenningen